The NADINA trial, presented as a plenary abstract at the American Society of Clinical Oncology meeting, provides confirmation of the idea of using immunotherapy in the neoadjuvant setting in melanoma, but the combination of Bristol Myers Squibb Company’s Opdivo (nivolumab) and Yervoy (ipilimumab) may not be the regimen that ultimately moves forward.
ASCO: NADINA Supports Neoadjuvant IO For Melanoma
The trial offers proof of concept for using Opdivo plus Yervoy as neoadjuvant treatment in melanoma; BMS notes a registrational trial is needed, but it is not clear which IO drugs will advance.
